YM-26734

HY-108609

YM-26734

YM-26734 is a competitive inhibitor of secretory phospholipase A2 (PLA2) that exhibits a broad inhibitory profile to several PLA2s[1].

519.55 €

565455

YM-254890

1125 €

HY-136182A

YM-244769

YM-244769 is a potent, selective and orally active Na+/Ca2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice[1][2][3].

740.34 €

HY-U00104

YM-46303

574.76 €

HY-100313A

YM-53601

YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo[1]. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent[2]. YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation[3].

1818.27 €

HY-100831

YM-58483

YM-58483 (BTP2) is the first selective and potent inhibitor of CRAC channels and subsequent Ca2+ signals[1]. YM-584832 is a blocker of store-operated Ca2+ entry (SOCE)[2].

772.81 €